SkinCeuticals
SkinCeuticals Triple Lipid Restore 2:4:2 Anti Aging Moisturiser
SkinCeuticals Triple Lipid Restore 2:4:2 Anti Aging Moisturiser
Couldn't load pickup availability
Product Overview
SkinCeuticals Triple Lipid Restore 2:4:2 addresses the primary mechanism of age-related skin barrier deterioration: the progressive depletion of intercellular lipids — ceramides, cholesterol, and fatty acids — that constitute the structural matrix of the stratum corneum barrier. These three lipid classes function synergistically: ceramides (primarily ceramides 1 and 3) fill intercellular gaps between corneocytes; cholesterol reinforces structural rigidity and permeability barrier function; and long-chain fatty acids maintain membrane fluidity and lipid composition balance. When any component is deficient, transepidermal water loss (TEWL) increases, barrier repair is impaired, and susceptibility to external irritants rises — a pattern clinically observed in aged, photo-damaged, and atopic skin.
The 2:4:2 designation refers to ceramides 2%, cholesterol 4%, fatty acids 2% — a ratio calibrated to deliver concentrations exceeding the standard 3:1:1 therapeutic ratio established in dermatological barrier repair literature (Elias and Feingold, Skin Pharmacology and Physiology, 2001). SkinCeuticals' proprietary formulation incorporates pure ceramides 1 and 3, enabling direct intercellular integration without requiring enzymatic processing in the stratum corneum. The formulation is substantiated by published lipidomics data demonstrating measurable increases in endogenous skin lipid composition following 8 weeks of twice-daily application.
Specifications
| Product Type | Corrective anti-aging moisturiser (dermocosmetic) |
| Manufacturer | SkinCeuticals (L'Oréal Groupe) |
| Key Active Lipids | Ceramides 1 and 3 (2%), Natural cholesterol (4%), Fatty acids (2%) — patented 2:4:2 ratio |
| Mechanism | Intercellular lipid matrix replenishment; stratum corneum barrier reinforcement; TEWL reduction |
| Clinical Evidence | 8-week study (ages 55–75): +66% smoothness, −35% laxity, +26% radiance; lipidomics: +57% ceramides, +50% cholesterol, +12% fatty acids |
| Skin Types | Dry, aging, mature, photo-damaged, barrier-compromised, post-procedure skin |
| Volume | 48 ml |
| Regulatory Status | Cosmetic preparation; no HSA therapeutic product registration required under Singapore Health Products Act (Cap. 122D) |
| Fragrance | Fragrance-free |
Clinical Indications
- Chronologically aged and photo-damaged skin with elevated TEWL and reduced stratum corneum lipid content, presenting with scaling, roughness, and barrier sensitivity
- Post-menopausal skin with oestrogen-decline-associated ceramide depletion, skin thinning, and reduced moisture-retention capacity
- Post-procedure skin recovery following laser resurfacing, chemical peels, microneedling, or dermabrasion — barrier restoration before reintroduction of active serums
- Atopic-prone or sensitised aging skin requiring fragrance-free, high-lipid barrier repair compatible with concurrent topical corticosteroid or calcineurin inhibitor therapy
- Xerosis in geriatric patients receiving institutional care, where skin integrity maintenance forms part of pressure injury prevention protocols
- Adjunctive skin-barrier maintenance in oncology patients experiencing xerosis and scaling as dermatological side effects of targeted therapy or immunotherapy
Frequently Asked Questions
Q: What is the clinical rationale for the 2:4:2 lipid ratio compared to standard moisturisers?
A: Standard dermatological barrier repair literature established that optimal repair requires an equimolar ratio of ceramides, cholesterol, and fatty acids. However, lipidomics studies show aging and photo-damaged skin exhibits disproportionate ceramide depletion relative to cholesterol loss. The 2:4:2 ratio delivers higher ceramide and fatty acid concentrations than standard 3:1:1 formulations, specifically addressing the lipid deficit profile of aging skin. The cholesterol concentration (4%) deliberately exceeds ceramide (2%), reflecting the faster rate of cholesterol-dependent barrier repair kinetics in aged keratinocytes.
Q: How does Triple Lipid Restore 2:4:2 interact with retinoid or active-ingredient regimens used in Singapore aesthetic clinics?
A: Triple Lipid Restore 2:4:2 is specifically compatible with retinoid-based regimens (tretinoin, retinol, adapalene) where barrier disruption is a common side effect. The high lipid content counteracts retinoid-induced xerosis and accelerated TEWL without occluding the skin or impeding retinoid receptor activity. In clinical protocols, it is applied as the final moisturisation step after water-based serums (vitamin C, niacinamide) and before SPF in the morning routine, and as the terminal step in evening retinoid protocols. It serves as the primary maintenance moisturiser in post-laser and post-peel protocols during the barrier restoration phase.
Q: Is Triple Lipid Restore 2:4:2 supported by dermatology society guidelines?
A: Ceramide-containing moisturisers are recommended by the American Academy of Dermatology (AAD) and European Academy of Dermatology and Venereology (EADV) as first-line adjunctive barrier maintenance in atopic dermatitis management. For non-atopic aging skin, ceramide replenishment is supported by published RCTs demonstrating statistically significant improvements in TEWL, hydration, and surface roughness. SkinCeuticals Triple Lipid Restore 2:4:2 is substantiated by proprietary lipidomics outcome data confirming measurable increases in endogenous skin ceramides, cholesterol, and fatty acids following consistent application.
Q: Is SkinCeuticals Triple Lipid Restore 2:4:2 available in Singapore, and through what channels?
A: Yes, Triple Lipid Restore 2:4:2 is available in Singapore through EMIS Asia as an authorised SkinCeuticals distributor. SkinCeuticals is a professional dermocosmetic brand distributed through dermatology clinics, plastic surgery practices, aesthetic medicine centres, and authorised medical aesthetics retailers in Singapore. It is classified as a cosmetic preparation and does not require HSA therapeutic product registration. EMIS Asia maintains Singapore local stock with same-week dispatch for clinic procurement orders.
Share
